Introducer & pacing leads ישראל - עברית - Ministry of Health

introducer & pacing leads

שילה חדשנות רפואית בע"מ - רופא - arterial introducer

אורנסיה 250 מג ישראל - עברית - Ministry of Health

אורנסיה 250 מג

bristol, myers squibb (israel) limited, israel - abatacept - אבקה להכנת תמיסה מרוכזת לעירוי - abatacept 250 mg - abatacept - abatacept - orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease modifying anti rheumatic drugs (dmards) including methotrexate (mtx) or a tnf-alpha inhibitor.a reduction in the progression of joint damage and improvement of physical function have been demonstrated during combination treatment with abatacept and methotrexate.polyarticular juvenile idiopathic arthritis:orencia in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (jia) in paediatric patients 6 years of age and older who have had an insufficient response to other dmards including at least one tnf inhibitor. orencia has not been studied in children under 6 years old.

אורנסיה 125 מג תת - עורי ישראל - עברית - Ministry of Health

אורנסיה 125 מג תת - עורי

bristol, myers squibb (israel) limited, israel - abatacept - תמיסה להזרקה - abatacept 125 mg/ml - abatacept - abatacept - orencia is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. orencia may be used as monotherapy or concomitantly with disease-modifying antirheumatic drugs (dmards) other than tumor necrosis factor (tnf) antagonists.

אקטמרה 20 מגמל I.V. ישראל - עברית - Ministry of Health

אקטמרה 20 מגמל i.v.

roche pharmaceuticals (israel) ltd - tocilizumab - תרכיז להכנת תמיסה לאינפוזיה - tocilizumab 20 mg/ml - tocilizumab - tocilizumab - actemra (tocilizumab) is indicated for reducing signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis who had an inadequate response to one or more dmards (disease modifying antirhematic drugs) or tnf antagonists or in whom dmards cannot be used. actemra can be used alone or in combination with methotrexate or other dmards.actemra® has been shown to reduce progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. actemra® is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older.

אקטמרה 162 מג S.C. ישראל - עברית - Ministry of Health

אקטמרה 162 מג s.c.

roche pharmaceuticals (israel) ltd - tocilizumab - תמיסה להזרקה - tocilizumab 162 mg / 0.9 ml - tocilizumab

פלולן אפופרוסטנול 1500 מקג לעירוי ישראל - עברית - Ministry of Health

פלולן אפופרוסטנול 1500 מקג לעירוי

glaxo smith kline (israel) ltd - epoprostenol as sodium - אבקה להכנת תמיסה לאינפוזיה - epoprostenol as sodium 1.5 mg/vial - epoprostenol - epoprostenol - flolan is indicated for the long-term intravenous treatment of primary arterial pulmonary hypertension and arterial pulmonary hypertension associated with the scleroderma spectrum of disease in nyha class iii and class iv patients who do not respond to conventional therapy.

סימזיה ישראל - עברית - Ministry of Health

סימזיה

neopharm ltd, israel - certolizumab pegol - תמיסה להזרקה - certolizumab pegol 200 mg/ml - certolizumab pegol

אילומדין ישראל - עברית - Ministry of Health

אילומדין

bayer israel ltd - iloprost - תרכיז להכנת תמיסה לאינפוזיה - iloprost 0.1 mg/ml - iloprost - iloprost - peripheral arterial occlusive disease (stage 3 and 4 of fontaine's classification) in advanced arteriosclerosis, in whom surgery or angioplasty therapy is not possible.thromboangitis obliterans (buerger's disease) with critical limb ischemia in cases where revascularisation is not indicated and severe disabling raynaud's phenomenon .